Organigram Announces Record Q2 Financial Results – Net Income of $1.1 Million

MONCTON, NB, April 24, 2018 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQB:OGRMF) (the "Company" or "Organigram"), a leading licensed producer of medical marijuana based in Moncton, New Brunswick, is pleased to announce its financial results for the three and six-months ended February 28, 2018. 

"We are incredibly proud of what we have achieved in Q2 as we registered record sales and a profit for the quarter," said Greg Engel the Company's CEO, "but we have also significantly bolstered our balance sheet and from an operational and sales and marketing perspective we are well positioned to take full advantage of not only the medical market but also the burgeoning adult recreational and international opportunities as well."

Operational and Financial Highlights

  • Record net sales for both the three-month and six-months ended February 28, 2018; 
  • Record sales of cannabis oil for both the three-month and six-months ended February 28, 2018; 
  • Record yields per plant in the quarter ended February 28, 2018 with projected improvements in yields in Q3-2018 which, along with efficiencies in production, should allow the Company to realize newer lows in production costs per gram (or gram equivalent) in Q3; 
  • Registered medical patients climbed to a record 13,000 by the end of the quarter; 
  • The Company closed two significant financings in the quarter.  An equity financing (with units issued consisting of one common share and ½ share purchase warrant) that closed on December 18, 2017 raising gross proceeds of $57.5 million and a convertible debenture offering (unsecured 6% coupon with a conversion option at $5.42/share) that closed on January 31, 2017 raising aggregate gross proceeds of $115 million; and 
  • The Company opened its Phase 2 expansion filling six rooms by the end of the quarter with the remaining 17 filled subsequent to the quarter.  Organigram began its first harvest from Phase 2 on "4/20" (April 20, 2018).


Summary of Financial Results


Three-months ended
February 28




Six-months ended 

February 28 




(in $000 except EPS)






Gross sales

$ 3,219

$ 1,445


$ 5,906

$ 3,675


Sales recovery (return)

$ 469

$ (2,026)


$ 469

$ (2,026)


Net sales2

$ 3,689

$ (581)


$ 6,375

$ 1,650


Cost of sales (incl. indirect production)

$ (1,550)

$ (3,029)


$ (3,340)

$ (3,808)


Gross margin (excluding FV adjustment)

$ 2,138

$ (3,610)


$ 3,035

$ (2,158)


FV adjust. on bio assets and inventories

$ 4,384

$ (367)


$ 5,106

$ (1,056)


Gross margin

$ 6,523

$ (3,977)


$ 8,141

$ (3,214)



General and admin

$ (2,002)

$ (914)


$ (3,187)

$ (1,455)


Sales and marketing

$ (1,147)

$ (705)


$ (2,280)

$ (1,372)


Share-based compensation (non-cash)

$ (1,154)

$ (291)


$ (1,899)

$ (565)


Net financing costs3

$ (1,143)

$ 133


$ (1,099)



Net income (loss)

$ 1,078

$ (5,755)


$ (324)

$ (6,511)



EPS (basic)

$ 0.009

$ (0.059)


$ (0.003)

$ (0.071)


EPS (diluted)

$ 0.008

$ (0.059)


$ (0.003)

$ (0.071)



Sales of (in thousands):


Dried cannabis flower (gr) 







Cannabis oil sold (ml)








1 Not meaningful.

Net sales consist of gross sales and sales recovery (return) and includes dried flower and cannabis oil sales, sales of accessories and revenues from the Company's wholly-owned subsidiary Trauma Healing Center.

3 Net financing costs consist of financing costs less any investment income earned.


Balance Sheet Highlights

At the end of the quarter the Company has:

    • $178 million in cash and short-term investments (up from $34 million at the August 31, 2017 year-end); 
    • $70 million in property, plant and equipment (up from $45 million at year-end); 
    • $12 million in current liabilities (up from $6 million at year-end); 
    • $96 million in long-term debt and convertible debentures (up from $3 million at year-end); 
    • 125 million outstanding shares as at February 28, 2018 (104 million at year-end); and 
    • 140 million fully-diluted shares as at February 28, 2018 (114 million at year-end) – including 7.7 million options (Aug.31/17 – 6.3 million), 8.1 million warrants (Aug.31/17 – 4.3 million), and 21.2 million shares (Aug.31/17 - nil) if the convertible debentures are converted at $5.42. 



  • Phase 3 expansion expected to be complete for the start of filling of rooms with first cannabis plants by June 1, 2018 bringing the Company's pro-forma run-rate capacity to 36,000 kg/yr; 
  • The Company intends to launch its adult-recreational brand strategy on or about May 15, 2018; and 
  • Organigram expects to announce one or more strategic or international investments in the upcoming quarter.


For more information, visit

About Organigram Holdings Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations ("ACMPR").

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors - including the availability of funds, consummation of definitive documentation, the results of financing efforts, crop yields - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Organigram Holdings Inc., Paolo De Luca, Chief Financial Officer,, (416) 661-0947; Organigram Holdings Inc., Dylan Rogers, Investor Relations Analyst,, (506) 232-0121

Have a question for us?

Call 1-844-644-4726 (1-844-OGI-GRAM) and the folks on our client support team like Dan, Janice and Jeff can answer any question you have.

Monday to Thursday: 8:30 AM to 8:00 PM 
Friday: 8:30 AM to 6:30 PM 
Fax: 1-855-267-1386

Stay informed. #DiscoverOGI.

Interested in keeping up with Organigram news? Subscribe to our mailing lists and stay up-to-date on Organigram products, patient programs, company news and investor relations. 

By signing up, I acknowledge that I can unsubscribe at any time, and I accept the terms, conditions and privacy policy.

If you wish to receive newsletters from Organigram Holdings Inc. and its subsidiaries, please provide your email address and click on the “Subscribe” button above. If we do not receive your consent, we may be unable to send you communications. If you have any questions, or if you wish to withdraw your consent at any time, please feel free to contact us by phone at 1-844-644-4726 or by email at By clicking “Subscribe” I consent to receipt of communications as indicated above.